AMR Accelerator

Antimicrobial resistance is a major health threat, causing 865,767 infections and 38,710 deaths in Europe in 2019 alone. Explore the burden of AMR for health-technology assessment in the paper by PrIMAVeRa project: https://lnkd.in/eWqfgSPJ. #AMRGlobalChallenge #SummerReading #OpenAccess Innovative Health Initiative (IHI) ERA4TB RespiriTB RespiriNTM UNITE4TB GSK Uppsala University BIOCOM Interrelations GmbH Universidad Carlos III de Madrid Lygature European Vaccine Initiative (EVI) BioVersys AG

We continue exploring the topic of #HealthCare, another fascinating work from ERA4TB: Dalia Dawoud, David Nicholls, and Sarosh Nagar. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis: https://lnkd.in/eYFgHujd #OpenAccess #TBresearch #SummerReading Charles III University of Madrid Pasteur Institute Synapse Managers Forschungszentrum Borstel, Leibniz Lungenzentrum Critical Path Institute (C-Path) Consiglio Nazionale delle Ricerche Uppsala University Public Health England Department of Health École polytechnique fédérale de Lausanne, EPFL University of Cologne Università degli Studi di Padova (UNIPD) / University of Padua Università di Pavia NICE - National Institute for Health and Care Excellence Sciensano Latvian Institute of Organic Synthesis BIOASTER Foundation de Coopération Scientifique QPS Netherlands BVl GSK Evotec The Janssen Pharmaceutical Companies of Johnson & Johnson Bill & Melinda Gates Foundation TB Alliance University of Dundee

Join our next REVIVE webinar to learn more about the Vivli AMR surveillance Data Challenge! Ian Morrissey, Rebecca Li, and Patricia Bradford will delve into the value of surveillance data in defining the medical need for new antimicrobials. #AMR #SurveillanceData #Antimicrobials #PowerOfAntibiotics

How does AMR affect healthcare in Europe? A systematic review and Bayesian meta-analysis from the PrIMAVeRa project about excess resource use and cost of drug-resistant infections for six key pathogens in Europe: https://lnkd.in/egwTBr3Z #AMRGlobalChallenge #SummerReading #OpenAccess Innovative Health Initiative (IHI) ERA4TB RespiriTB RespiriNTM UNITE4TB GSK Uppsala University BIOCOM Interrelations GmbH Charles III University of Madrid Lygature European Vaccine Initiative (EVI) BioVersys AG

Congratulations to the UNITE4TB consortium for this achievement!

After a short break, we are kicking off our summer reading campaign with the latest publication from ERA4TB! Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin. https://lnkd.in/eCkN-uvg #AMRGlobalChallenge #TBresearch #OpenAccess Innovative Health Initiative (IHI) RespiriTB RespiriNTM UNITE4TB GSK Uppsala University BIOCOM Interrelations GmbH Charles III University of Madrid Lygature European Vaccine Initiative (EVI) Vaccine Initiative BioVersys AG

Good luck to all our speakers presenting at the PAGE - Population Approach Group Europe meeting this week! If you are attending the meeting, make sure you check them out: 📢 Silvia Grandoni will present: Do differences in PK defeat similarities in immune system in non-human primates? Pharmacokinetic modelling of standard of care antitubercular drugs in marmosets 📢 Umberto Villani will present:Model-based characterisation of host-directed therapeutics against M. tuberculosis in an in vitro experimental model 📢 Peter Velickovic will present: Translational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis 📢 Enrico Mastrostefano will present: Integrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment 📢 Aris Dokoumetzidis will present: Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modeling  📢 Budi Octasari Susanto will present: An integrative translational framework for in vitro modelling for macozinone to support prediction of early human anti-tubercular efficacy #TBresearch #Tuberculosis #TB #earlystageresearch #drugdevelopment Innovative Health Initiative (IHI), AMR Accelerator

PrIMAVeRA project news! Divided into two long rounds in June, Consortium partners presented year two progress toward the project’s goal of developing a decision-making tool integrating an epidemiological repository with mathematical models to prioritise #vaccines and monoclonal antibodies for combating #AMR. During its third meeting with the Scientific Advisory Committee (SAC) they reviewed outcomes and progress, and to receive guidance for future plans. 🤝 Find meeting highlight and outcomes on this news item: https://lnkd.in/dg5m4dPd --- Partners: European Vaccine Initiative (EVI) (Coordinator) UMC Utrecht, University of Geneva, University of Verona, DTU - Technical University of Denmark, Institut Pasteur, The Hospital of Lithuanian University of Health Sciences Kauno klinikos, UK Health Security Agency, Instituto de Salud Carlos III, Université Grenoble Alpes, University of Oxford, University of Tübingen, GSK, Pfizer, The Janssen Pharmaceutical Companies of Johnson & Johnson, World Health Organization, Rambam Health Care Campus, The University of Edinburgh.    #PrIMAVeRa_AMR #EUfunded #vaccine #AntibioticResistance #StopSuperbugs This work has received support from the IMI2/EU/EFPIA Joint Undertaking Inno4Vac grant n° 101034420 [PrIMAVeRa]. This reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use made of the information contained therein. 

Our latest UNITE4TB Newsletter is out, packed with updates and insights on our ongoing efforts to accelerate the development of new treatment regimens for tuberculosis (TB). Here’s a sneak peek at what’s inside: 🔹 2024 Annual Consortium Meeting & Joint Symposium with ERA4TB: Highlights and key takeaways from this event, emphasizing the importance of collaborative efforts in TB research. 🔹 World TB Day Activities: A look back at our activities to mark this year's awareness day. 🔹 Upcoming UNITE4TB webinar: Join us on 27 June for an in-depth discussion on approaches to market-shaping and access to TB medicines. 🔹 Publications: New publications from the UNITE4TB Consortium 🔗👉 https://lnkd.in/esEEiJjc Subscribe to our newsletter for the latest news and updates (see link in comments) #UNITE4TB #EndTB #Newsletter #SubscribeNow #GlobalHealth #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.

We are excited about the COMBINE webinar tomorrow at 15:00 CEST! https://lnkd.in/ej2b9s4b Register even if you cannot attend the event to receive the webinar recording directly in your inbox! #GlobalAMRChallenge #DrugDevelopment #Antibiotics Innovative Health Initiative (IHI)